Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome
Files
Publication date
2022-08-15
Authors
Streng, Bianca M M
Bont, Marin
Delemarre, Eveline M
Binnendijk, Rob S
Smit, Gaby
den Hartog, Gerco
Coppus, Antonia M W
De Vries, Esther
Weijerman, Michel E
Lamberts, Regina
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by_nc_nd
Abstract
UNLABELLED: The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. CLINICAL TRIALS REGISTRATION: NCT05145348.
Keywords
Adult, Antibodies, Viral, Antibody Formation, BNT162 Vaccine, COVID-19/prevention & control, COVID-19 Vaccines, Down Syndrome, Humans, Prospective Studies, RNA, Messenger, SARS-CoV-2, Vaccination, SDG 3 - Good Health and Well-being
Citation
Streng, B M M, Bont, M, Delemarre, E M, Binnendijk, R S, Smit, G, den Hartog, G, Coppus, A M W, de Vries, E, Weijerman, M E, Lamberts, R, de Graaf, G, van der Klis, F R, Vidarsson, G, Rave, N, Bont, L J & Wildenbeest, J G 2022, 'Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome', Journal of Infectious Diseases, vol. 226, no. 4, pp. 673-677. https://doi.org/10.1093/infdis/jiac235